Literature DB >> 35043381

The Gpx4NIKO Mouse Is a Versatile Model for Testing Interventions Targeting Ferroptotic Cell Death of Spinal Motor Neurons.

Robert Cole Evans1, Liuji Chen1, Ren Na1, Kwangsun Yoo1, Qitao Ran2,3.   

Abstract

The degeneration and death of motor neurons lead to motor neuron diseases such as amyotrophic lateral sclerosis (ALS). Although the exact mechanism by which motor neuron degeneration occurs is not well understood, emerging evidence implicates the involvement of ferroptosis, an iron-dependent oxidative mode of cell death. We reported previously that treating Gpx4NIKO mice with tamoxifen to ablate the ferroptosis regulator glutathione peroxidase 4 (GPX4) in neurons produces a severe paralytic model resembling an accelerated form of ALS that appears to be caused by ferroptotic cell death of spinal motor neurons. In this study, in support of the role of ferroptosis in this model, we found that the paralytic symptoms and spinal motor neuron death of Gpx4NIKO mice were attenuated by a chemical inhibitor of ferroptosis. In addition, we observed that the paralytic symptoms of Gpx4NIKO mice were malleable and could be tapered by lowering the dose of tamoxifen, allowing for the generation of a mild paralytic model without a rapid onset of death. We further used both models to evaluate mitochondrial reactive oxygen species (mtROS) in the ferroptosis of spinal motor neurons and showed that overexpression of peroxiredoxin 3, a mitochondrial antioxidant defense enzyme, ameliorated symptoms of the mild but not the severe model of the Gpx4NIKO mice. Our results thus indicate that the Gpx4NIKO mouse is a versatile model for testing interventions that target ferroptotic death of spinal motor neurons in vivo.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Ferroptosis; Glutathione peroxidase 4; Mitochondrial reactive oxygen species; Motor neuron degeneration; Peroxiredoxin 3

Mesh:

Substances:

Year:  2022        PMID: 35043381      PMCID: PMC9035057          DOI: 10.1007/s12640-021-00469-0

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.978


  28 in total

Review 1.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

2.  Synchronized renal tubular cell death involves ferroptosis.

Authors:  Andreas Linkermann; Rachid Skouta; Nina Himmerkus; Shrikant R Mulay; Christin Dewitz; Federica De Zen; Agnes Prokai; Gabriele Zuchtriegel; Fritz Krombach; Patrick-Simon Welz; Ricardo Weinlich; Tom Vanden Berghe; Peter Vandenabeele; Manolis Pasparakis; Markus Bleich; Joel M Weinberg; Christoph A Reichel; Jan Hinrich Bräsen; Ulrich Kunzendorf; Hans-Joachim Anders; Brent R Stockwell; Douglas R Green; Stefan Krautwald
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

3.  Optimal methods to characterize the G93A mouse model of ALS.

Authors:  Francisco J Miana-Mena; Maria J Muñoz; Gema Yagüe; Mario Mendez; Maria Moreno; Jesús Ciriza; Pilar Zaragoza; Rosario Osta
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2005-03

4.  Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis.

Authors:  Marzia Perluigi; H Fai Poon; Kenneth Hensley; William M Pierce; Jon B Klein; Vittorio Calabrese; Carlo De Marco; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2005-04-01       Impact factor: 7.376

5.  Regulation of ferroptotic cancer cell death by GPX4.

Authors:  Wan Seok Yang; Rohitha SriRamaratnam; Matthew E Welsch; Kenichi Shimada; Rachid Skouta; Vasanthi S Viswanathan; Jaime H Cheah; Paul A Clemons; Alykhan F Shamji; Clary B Clish; Lewis M Brown; Albert W Girotti; Virginia W Cornish; Stuart L Schreiber; Brent R Stockwell
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

6.  Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients.

Authors:  W A Pedersen; W Fu; J N Keller; W R Markesbery; S Appel; R G Smith; E Kasarskis; M P Mattson
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

7.  Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS.

Authors:  E D Hall; P K Andrus; J A Oostveen; T J Fleck; M E Gurney
Journal:  J Neurosci Res       Date:  1998-07-01       Impact factor: 4.164

Review 8.  Ferroptosis and Cancer: Mitochondria Meet the "Iron Maiden" Cell Death.

Authors:  Anna Martina Battaglia; Roberta Chirillo; Ilenia Aversa; Alessandro Sacco; Francesco Costanzo; Flavia Biamonte
Journal:  Cells       Date:  2020-06-20       Impact factor: 6.600

9.  Overexpression of ferroptosis defense enzyme Gpx4 retards motor neuron disease of SOD1G93A mice.

Authors:  Liuji Chen; Ren Na; Kirsten Danae McLane; Cody Sylvester Thompson; Ju Gao; Xinglong Wang; Qitao Ran
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.996

Review 10.  Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration.

Authors:  Moataz Abdalkader; Riikka Lampinen; Katja M Kanninen; Tarja M Malm; Jeffrey R Liddell
Journal:  Front Neurosci       Date:  2018-07-10       Impact factor: 4.677

View more
  2 in total

Review 1.  Mechanisms of Ferroptosis and Emerging Links to the Pathology of Neurodegenerative Diseases.

Authors:  Yiyan Sun; Xiaohuan Xia; Diksha Basnet; Jialin C Zheng; Jian Huang; Jianhui Liu
Journal:  Front Aging Neurosci       Date:  2022-06-28       Impact factor: 5.702

2.  The Classification and Prediction of Ferroptosis-Related Genes in ALS: A Pilot Study.

Authors:  Qianqian Zhang; Huihui Zhao; Maotao Luo; Xi Cheng; Yanan Li; Qingyang Li; Zheng Wang; Qi Niu
Journal:  Front Genet       Date:  2022-07-08       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.